Please find enclosed financial result for the year ended 31.03.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tejnaksh Healthcare reported audited FY25 results with standalone revenue from operations of ₹879.78 lakhs (vs ₹822.15 lakhs in FY24, up ~7%) and standalone profit after tax of ₹262.15 lakhs (vs ₹181.25 lakhs, up ~44.6%). On a consolidated basis, revenue grew to ₹1,289.71 lakhs (from ₹1,217.51 lakhs, ~5.9% higher) and PAT rose to ₹223.05 lakhs (from ₹176.39 lakhs, ~26.4% higher). Standalone EPS improved to ₹1.29 from ₹0.89. The company also received an arbitration award of ₹170 lakhs from a non-compete dispute linked to a 2016–17 acquisition, and adjusted net proceeds of ~₹139.12 lakhs against goodwill, reducing it from ₹350 lakhs to ₹210.88 lakhs to be amortized over five years from FY26. Auditor Maheshwari & Co. issued an unmodified (clean) opinion on both standalone and consolidated results. Borrowings dropped sharply from ₹410.94 lakhs to ₹63.20 lakhs.
Strong PAT growth driven by margin expansion and lower finance costs is a positive signal for shareholders, although revenue growth is modest. The clean audit opinion and sharp debt reduction strengthen the balance sheet, while the one-time arbitration recovery adds a non-recurring boost to FY25 earnings.